556 related articles for article (PubMed ID: 36814688)
21. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis.
Rieser CJ; Narayanan S; Bahary N; Bartlett DL; Lee KK; Paniccia A; Smith K; Zureikat AH
J Surg Oncol; 2021 Oct; 124(5):801-809. PubMed ID: 34231222
[TBL] [Abstract][Full Text] [Related]
22. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
Front Oncol; 2020; 10():621937. PubMed ID: 33520728
[TBL] [Abstract][Full Text] [Related]
23. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
24. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach.
Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA
Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681
[TBL] [Abstract][Full Text] [Related]
25. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
Ratnayake B; Savastyuk AY; Nayar M; Wilson CH; Windsor JA; Roberts K; French JJ; Pandanaboyana S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640720
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
Wang C; Tan G; Zhang J; Fan B; Chen Y; Chen D; Yang L; Chen X; Duan Q; Maimaiti F; Du J; Lin Z; Gu J; Luo H
Front Oncol; 2022; 12():828223. PubMed ID: 35785193
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis.
MacCurtain BM; Quirke NP; Thorpe SD; Gallagher TK
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34205335
[TBL] [Abstract][Full Text] [Related]
29. The Role of the Microbiome in Pancreatic Cancer.
Miyabayashi K; Ijichi H; Fujishiro M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139638
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in targeted therapy for pancreatic adenocarcinoma.
Fang YT; Yang WW; Niu YR; Sun YK
World J Gastrointest Oncol; 2023 Apr; 15(4):571-595. PubMed ID: 37123059
[TBL] [Abstract][Full Text] [Related]
32. The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.
Muller M; Haghnejad V; Schaefer M; Gauchotte G; Caron B; Peyrin-Biroulet L; Bronowicki JP; Neuzillet C; Lopez A
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205742
[TBL] [Abstract][Full Text] [Related]
33. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
Rieser CJ; Zenati M; Narayanan S; Bahary N; Lee KK; Paniccia A; Bartlett DL; Zureikat AH
Ann Surg Oncol; 2021 Oct; 28(11):6264-6272. PubMed ID: 33748894
[TBL] [Abstract][Full Text] [Related]
34. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
[TBL] [Abstract][Full Text] [Related]
35. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
37. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
[TBL] [Abstract][Full Text] [Related]
39. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]